Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 1 de 1
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Neuroendocrinology ; 107(4): 340-354, 2018.
Artículo en Inglés | MEDLINE | ID: mdl-30208370

RESUMEN

BACKGROUND/AIMS: Abuse of toluene products (e.g., glue-sniffing) primarily occurs during adolescence and has been associated with appetite suppression and weight impairments. However, the metabolic phenotype arising from adolescent inhalant abuse has never been fully characterised, and its persistence during abstinence and underlying mechanisms remain unknown. METHODS: Adolescent male Wistar rats (post-natal day 27) were exposed to inhaled toluene (10,000 ppm) (n = 32) or air (n = 48) for 1 h/day, 3 days/week for 4 weeks, followed by 4 weeks of abstinence. Twenty air rats were pair-fed to the toluene group, to differentiate the direct effects of toluene from under-nutrition. Food intake, weight, and growth were monitored. Metabolic hormones were measured after exposure and abstinence periods. Energy expenditure was measured using indirect calorimetry. Adrenal function was assessed using adrenal histology and hormone testing. RESULTS: Inhalant abuse suppressed appetite and increased energy expenditure. Reduced weight gain and growth were observed in both the toluene and pair-fed groups. Compared to the pair-fed group, and despite normalisation of food intake, the suppression of weight and growth for toluene-exposed rats persisted during abstinence. After exposure, toluene-exposed rats had low fasting blood glucose and insulin compared to the air and pair-fed groups. Consistent with adrenal insufficiency, adrenal hypertrophy and increased basal adrenocorticotropic hormone were observed in the toluene-exposed rats, despite normal basal corticosterone levels. CONCLUSIONS: Inhalant abuse results in negative energy balance, persistent growth impairment, and endocrine changes suggestive of adrenal insufficiency. We conclude that adrenal insufficiency contributes to the negative energy balance phenotype, potentially presenting a significant additional health risk for inhalant users.


Asunto(s)
Enfermedades de las Glándulas Suprarrenales/inducido químicamente , Trastornos del Crecimiento/inducido químicamente , Abuso de Inhalantes/complicaciones , Enfermedades Metabólicas/inducido químicamente , Maduración Sexual , Adolescente , Conducta del Adolescente/efectos de los fármacos , Conducta del Adolescente/fisiología , Desarrollo del Adolescente/efectos de los fármacos , Enfermedades de las Glándulas Suprarrenales/metabolismo , Enfermedades de las Glándulas Suprarrenales/fisiopatología , Glándulas Suprarrenales/fisiopatología , Animales , Apetito/efectos de los fármacos , Peso Corporal/efectos de los fármacos , Modelos Animales de Enfermedad , Ingestión de Alimentos/efectos de los fármacos , Trastornos del Crecimiento/metabolismo , Trastornos del Crecimiento/fisiopatología , Humanos , Abuso de Inhalantes/metabolismo , Abuso de Inhalantes/patología , Abuso de Inhalantes/fisiopatología , Masculino , Enfermedades Metabólicas/metabolismo , Enfermedades Metabólicas/fisiopatología , Actividad Motora/efectos de los fármacos , Fenotipo , Ratas , Ratas Wistar , Maduración Sexual/efectos de los fármacos , Maduración Sexual/fisiología , Tolueno/toxicidad
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA